Mitomycin C induces pulmonary vascular endothelial‐to‐mesenchymal transition and pulmonary veno‐occlusive disease via Smad3‐dependent pathway in rats

Chenting Zhang,Wenju Lu,Xiaoyun Luo,Shiyun Liu,Yi Li,Qiuyu Zheng,Wenyan Liu,Xuefen Wu,Yuqin Chen,Qian Jiang,Zizhou Zhang,Guoping Gu,Jiyuan Chen,Haixia Chen,Jing Liao,Chunli Liu,Cheng Hong,Haiyang Tang,Dejun Sun,Kai Yang,Jian Wang
DOI: https://doi.org/10.1111/bph.15314
IF: 7.3
2020-12-14
British Journal of Pharmacology
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Purpose</h3><p>Pulmonary veno‐occlusive disease (PVOD) is a rare disease characterized by the obstruction of small pulmonary veins leading to pulmonary hypertension. However, the mechanisms underlying pulmonary vessel occlusion remain largely unclear.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental Approach</h3><p>A mitomycin C (MMC)‐induced PVOD rat model was used as <i>in vivo</i> animal model; and primarily cultured rat pulmonary microvascular endothelial cells (PMVECs) were used as <i>in vitro</i> cell model. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Our data suggested an endothelial‐to‐mesenchymal transition (EndoMT) may be present in the pulmonary microvessels isolated from either PVOD patients or MMC‐induced PVOD rats. In compare to the control vessels, vessels from both PVOD patients and PVOD rats represented co‐localized staining of specific endothelial marker von Willebrand factor (vWF) and mesenchymal marker α‐smooth muscle actin (α‐SMA), suggesting the presence of cells that co‐express endothelial and mesenchymal markers. Then, in both the lung tissues of MMC‐induced PVOD rats and MMC‐treated rat PMVECs, decreased levels of endothelial markers (e.g. VE‐cadherin, CD31) and increased mesenchymal markers (e.g. Vimentin, Fibronectin, α‐SMA) were detected, also indicating EndoMT. Moreover, MMC induced activation of the TGFβ/Smad3/Snail axis, while blockage of this pathway with either specific Smad3 inhibitor (SIS3) or small interfering RNA (siRNA) against Smad3, both dramatically abolished the MMC‐induced EndoMT. Notably, treatment with SIS3 remarkably prevented the pathogenesis of MMC‐induced PVOD in rats.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Our data indicated that targeted inhibition of Smad3 leads to a potential, novel strategy for PVOD therapy, likely by inhibiting the EndoMT in pulmonary microvasculature.</p></section>
pharmacology & pharmacy
What problem does this paper attempt to address?